Browse Category: Cancer Research

Oncotarget Helps Doctors to Diagnose Patients

Science and research are intertwined in offering the best medical solutions in treatment. Historically, science has proven to be the best option in finding treatment for diseases. It offers a plethora of opportunities for both researchers and scientists to find treatment opportunities. Additionally, the platform has offered researchers, scientists and donors the chance to launch key tools in finding different treatment options for diseases. Many diseases with cancer as a good example have been destroying families by claiming lives. Cancer was a mystery for decades.


The launching of scientific tools to aid in research has significantly contributed to the understanding of the disease with many research options coming up to aid in treatment. Science has tremendously played a pivotal role in finding treatment for cancer. It is also the same scientific research that has contributed to the generation of vital, data and information via research. The same platform has launched key tools like journals, online social media platforms and workshops to find treatment. One tool that science has offered is Oncotarget, a vital, peer-reviewed, scientific journal. The journal commits to disseminating critical information on science, diseases and their treatment.


Globally, Oncotarget has been used to establish key findings in research and degenerative medicine. It specializes in establishing key details pertaining to diseases. It also shares the same details with physicians and research scientists. From campaigns to sensitization on the global drive towards acquiring a community that is disease free, Oncotarget has been useful in highlighting key effects and symptoms of certain unhealthy lifestyles. One key issue that has the journal has been highlighting lately is the use of e-cigars, something most users thought was healthier compared to normal cigars. Oncotarget featured an article that states e-cigars have a bad side effect to health. It is proven that the e-cigar damages gum tissues.


Being an open source of scientific information, Oncotarget has been instrumental in the battle against cancer. The journal is flexible at disseminating useful data concerning, cancer, diabetes, side effects of using cigarettes and many others. With the assistance of an experience editor, Oncotarget is set to expand its editorial issues because of the high, rising, demand.

Exploring The Contribution of Clay Siegall To Cancer Research


Research aimed at delivering new ways of treating cancer has been on for many years. In the past decade, many companies in the pharmaceutical industry have pumped more funds and energy into cancer research and their objective has been to come up with a reliable technology that can make cancer treatment easier and more successful. Among these companies is Seattle Genetics, a company that has proved to offer modern solutions to the development of the industry. Seattle Genetics has been funding and pursuing research to unveil new treatment methods for cancer.

Under the leadership of Clay Siegall, who also co-founded the company, Seattle Genetics has managed to release different drug pipelines like ADCETRIS, which has recorded a lot of success across the world. Most importantly, Seattle Genetics developed the ADC Technology, whose focus is discriminating cells while treating cancer to ensure only infected cells are eliminated.

The traditional radiation method of killing cancer cells does not effectively achieve this as it also kills cells that are healthy, thereby weakening the patient further. ADC will ensure patients are not exposed to the risk of losing healthy cells while receiving treatment. Seattle Genetics has also been able to invite other companies to support the development of superior drug pipelines and technologies that could help them to achieve a milestone in cancer treatment.

About Clay Siegall

Clay B. Siegall, the founder, CEO and President of Seattle Genetics, is a clinical scientist, whose passion in medicine has motivated him to invest more into cancer research and the development of treatment options that are geared towards enhancing treatment practices. His company has been sponsoring research in this field and over the past 10 years, they unveiled several products, among them the ADC Technology, which allows for better ways of treating cancer.

He also expressed satisfaction in the introduction of ADCETRIS to be part of the drug pipelines the company produces to support cancer treatment. Clay Siegall acquired a bachelor’s degree in Zoology from the Maryland University and a PhD in Genetics from Washington University. Prior to launching Seattle Genetics, he served at the National Institute of Health.